OBJECTIVE: This report extracts important considerations for determining and applying clinically significant differences in quality of life (QOL) measures from six published articles written by 30 international experts, in the field of QOL assessment and evaluation. The original six articles were presented at the Symposium on Clinical Significance of Quality of Life Measures in Cancer Patients at the Mayo Clinic in April 2002 and subsequently were published in Mayo Clinic Proceedings. PRINCIPAL FINDINGS: Specific examples and formulas are given for anchor-based methods, as well as distribution-based methods that correspond to known or relevant anchors to determine important differences in QOL measures. Important prerequisites for clinical significance associated with instrument selection, responsiveness, and the reporting of QOL trial results are provided. We also discuss estimating the number needed to treat (NNT) relative to clinically significant thresholds. Finally, we provide a rationale for applying group-derived standards to individual assessments. CONCLUSIONS: While no single method for determining clinical significance is unilaterally endorsed, the investigation and full reporting of multiple methods for establishing clinically significant change levels for a QOL measure, and greater direct involvement of clinicians in clinical significance studies are strongly encouraged.
OBJECTIVE: This report extracts important considerations for determining and applying clinically significant differences in quality of life (QOL) measures from six published articles written by 30 international experts, in the field of QOL assessment and evaluation. The original six articles were presented at the Symposium on Clinical Significance of Quality of Life Measures in CancerPatients at the Mayo Clinic in April 2002 and subsequently were published in Mayo Clinic Proceedings. PRINCIPAL FINDINGS: Specific examples and formulas are given for anchor-based methods, as well as distribution-based methods that correspond to known or relevant anchors to determine important differences in QOL measures. Important prerequisites for clinical significance associated with instrument selection, responsiveness, and the reporting of QOL trial results are provided. We also discuss estimating the number needed to treat (NNT) relative to clinically significant thresholds. Finally, we provide a rationale for applying group-derived standards to individual assessments. CONCLUSIONS: While no single method for determining clinical significance is unilaterally endorsed, the investigation and full reporting of multiple methods for establishing clinically significant change levels for a QOL measure, and greater direct involvement of clinicians in clinical significance studies are strongly encouraged.
Authors: Mirjam A G Sprangers; Carol M Moinpour; Timothy J Moynihan; Donald L Patrick; Dennis A Revicki Journal: Mayo Clin Proc Date: 2002-06 Impact factor: 7.616
Authors: David Cella; David T Eton; Diane L Fairclough; Philip Bonomi; Anne E Heyes; Cheryl Silberman; Michael K Wolf; David H Johnson Journal: J Clin Epidemiol Date: 2002-03 Impact factor: 6.437
Authors: Michael Seid; Elizabeth J D'Amico; James W Varni; Jennifer K Munafo; Maria T Britto; Carolyn M Kercsmar; Dennis Drotar; Eileen C King; Lynn Darbie Journal: J Pediatr Psychol Date: 2011-12-13
Authors: Stina Bladh; Maria H Nilsson; Gun-Marie Hariz; Albert Westergren; Jeremy Hobart; Peter Hagell Journal: J Neurol Date: 2011-09-29 Impact factor: 4.849
Authors: Eve Wittenberg; Elkan Halpern; Nomia Divi; Lisa A Prosser; Sally S Araki; Jane C Weeks Journal: Qual Life Res Date: 2006-05 Impact factor: 4.147
Authors: Jonathan L Berliner; Dane J Brodke; Vanessa Chan; Nelson F SooHoo; Kevin J Bozic Journal: Clin Orthop Relat Res Date: 2017-01 Impact factor: 4.176